The Global Nucleic Acid Isolation and Purification Market is segmented into drug discovery & development, precision medicine, diagnostics, agriculture and animal research, and other, based on ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy US lab equipment supplier Sigma-Aldrich for $17 billion, its biggest-ever deal. In 2019, Merck ...

The global drug discovery enzymes market is poised for significant expansion, projected to grow from USD 932.4 million in 2023 to USD 1,751.3 million by 2033, advancing at a compound annual growth ...

Hydrochloric acid (37%) was obtained from Merck KGaA (Darmstadt, Germany). Benzaldehyde (+99%, chlorine free) was purchased from Sigma-Aldrich (Milan, Italy). Tetrahydrofuran (THF) (Merck, Darmstadt, ...

Sigma-Aldrich Corporation is a life science and high technology company. The Company develops, manufactures, purchases and distributes a range of chemicals, biochemicals and equipment globally.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...